Bal Pharma
BALPHARMA • Pharmaceuticals & Biotechnology
Last Price
₹83.04
Market Cap
₹132.21 Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-10-27Sector: Bal Pharma (BALPHARMA) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry. NSE sector rotation chart
Sharia rating: Bal Pharma is rated Not halal by a specialist third-party provider. Full list of halal NSE stocks
27% below its 52-week high
Price trend
Neutral
Over the last 6 months, Bal Pharma's share price has risen, doing better than 44% of Pharmaceuticals & Biotechnology stocks.
Institutional activity
Neutral
Trading patterns over recent weeks show no clear sign of institutions buying or selling Bal Pharma (buying score 1/10, selling score 1/10).
Model rank
Strongly positive
Our model's 5-day return score puts Bal Pharma ahead of 99% of NSE stocks. The model is fairly confident in this score (97%).
Ease of trading
Elevated
Some signs that trading in Bal Pharma is thinner than usual (risk score 4/10). Volume has been below normal for 9 days.
Price vs profits
Typical
The share price is 21× last year's profit per share — about in the typical range for NSE stocks (15–30×).
The wider Indian market is in a crisis regime — unusually sharp moves (model 100% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Bal Pharma (BALPHARMA)
Bal Pharma is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE083D01012). This page brings together the quantitative research signals our models compute for BALPHARMA: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Bal Pharma's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.